We are in a uniquely fertile time for genetic discovery and we are alert to new drug targets and how we can apply genetic knowledge in
We discover and develop our drugs both independently and in collaboration with pharmaceutical, biotechnology and academic partners. In all our partner collaborations we apply our proprietary technologies, including the Kymouse™ platform, to discover, develop and commercialise monoclonal antibodies to difficult and novel drug targets in our therapeutic areas of immuno-oncology, haematology, inflammation and infectious disease.
We have mature partnerships to develop products that serve patients with high unmet medical needs. Our partners access our team of proven drug-discovery and development scientists employing our suite of proprietary technologies including:
- our flagship Kymouse™ platform that rapidly generates candidate-quality monoclonal antibodies with the desired affinity, potency, epitope, mechanism of action, species cross-reactivity and biophysical properties;
- our B-cell screening platform that deeply mines the Kymouse™ and isolates candidate-quality molecules;
- our KO/KI platform that enables gene knock-outs and knock-ins on a Kymouse™ background to pursue challenging drug targets.
Genetic Variation and Precision Medicine partnership opportunities
We have a developing interest in the therapeutic application of genomics as it relates to antibody discovery.
We have filed and been granted a number of patents in the USA that relate to targeting antibodies and antibody fragments to rare human variants (allelic variation) in human gene targets of interest to treat unmet medical conditions such as cancer, hypercholesterolemia, pain, ophthalmology and rheumatoid arthritis.
We are willing to enter into licensing or collaborative discussions
We are passionate to pursue new collaborations and partnerships that maximise value and impact on patients' lives.
To find out more, please contact: email@example.com